Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29042052 | 0.94 | USP30 (0.47) | FPR2USP30GPR119BACE1HCAR1 | |
| SCHEMBL29042019 | 0.94 | USP30 (0.47) | FPR2USP30GPR119BACE1HCAR1 | |
| SCHEMBL25210991 | 0.91 | USP30 (0.46) | FPR2USP30GPR119BACE1HCAR1 | |
| SCHEMBL28456342 | 0.89 | USP30 (0.44) | FPR2USP30GPR119BACE1 | |
| SCHEMBL30694222 | 0.88 | OPRM1 (0.44) | FPR2USP30GPR119BACE1HCAR1 | |
| SCHEMBL28463632 | 0.88 | FPR2 (0.48) | FPR2USP30BACE1HCAR1FGFR3 | |
| SCHEMBL20134846 | 0.87 | CNR1 (0.47) | GPR119HCAR1MAPT | |
| SCHEMBL17109250 | 0.86 | KMT2A (0.44) | GPR119HCAR1KDM4E | |
| SCHEMBL20135591 | 0.84 | GPR119 (0.50) | GPR119HCAR1METDDB1CRBN | |
| SCHEMBL24779505 | 0.83 | DPP4 (0.41) | GPR119HCAR1DDB1CRBNKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| EP-4436961-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2024131942-A1 | CYCLOPROPANE TLR7 AND TLR8 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海深势唯思科技有限责任公司 | 2024-06-27 | — | — | WO | disclosed |
| CN-118239959-A | Cyclopropane TLR7 and 8 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117986262-A | Condensed bicyclic compounds, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-116478145-B | ALK2 kinase inhibitors | 杭州邦顺制药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| CN-111662232-B | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2022-08-02 | — | — | CN | disclosed |
| CN-107922347-B | Novel imide derivatives and their use as pharmaceuticals | 田边三菱制药株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
| CN-111662232-A | Small molecule compound with 2H-indazole structure and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-09-15 | — | — | CN | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | FPR2 2193/4885USP30 3026/4885GPR119 4012/4885 |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | FPR2 1086/4885USP30 427/4885GPR119 799/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | FPR2 1501/4885USP30 458/4885GPR119 997/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | FPR2 1341/4885USP30 2860/4885GPR119 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.